Skip to main content
. 2015 Aug 19;10(8):e0135236. doi: 10.1371/journal.pone.0135236

Fig 4. Suppression of ROS production inhibited nedaplatin-induced cell death.

Fig 4

(A) HNE1/DDP cells were incubated with varied concentrations of nedaplatin for 12 h. Then, the samples were prepared as described in Materials and Methods. All data are expressed as means ± SD from five independent experiments. *p< 0.05. (B) HNE1/DDP cells were incubated with 6.0 μg/ml nedaplatin in the presence or absence of Baf A1 for 6 h. Then, the cells were treated as described in A. (C) HNE1/DDP cells were treated with 6.0 μg/ml nedaplatin for 12 h in the absence or presence of NAC (10 mM). The cells were treated as described in A. *p<0.05. (D) The LC3 I/II levels were examined by western blot after the nedaplatin treatment with or without of NAC (10 mM) for 48 h. (E) HNE1/DDP cells were treated with 6.0 μg/ml nedaplatin for 48 h in the absence or presence of NAC (10 mM). The cell viability was determined as described in Materials and Methods. Data are mean ± SD from five independent experiments. ***p<0.001 compared to nedaplatin only.